CD36

Across TCGA pan-cancer cohorts, CD36 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD36 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD36 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD36 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, CCRCC, and COAD are the cancer types where CD36 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.847	0.980	.011	11	view →
CCRCC	OS	Quartile	All	0.924	0.643	.005	7	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
PDAC	OS	Tertile	III,IV	0.328	0.932	.031	2	view →
HNSC	OS	Tertile	All	0.816	0.607	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD36–LUAD (DFS)

Open the LUAD breakdown →